These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 31240841)
1. Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: A systematic review and meta-analysis. Hellfritzsch M; Adelborg K; Damkier P; Paaske Johnsen S; Hallas J; Pottegård A; Grove EL Basic Clin Pharmacol Toxicol; 2020 Jan; 126(1):21-31. PubMed ID: 31240841 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies. Archontakis-Barakakis P; Li W; Kalaitzoglou D; Tzelves L; Manolopoulos A; Giannopoulos S; Giamouzis G; Giannakoulas G; Batsidis A; Palaiodimos L; Ntaios G; Lip GYH; Kokkinidis DG Br J Clin Pharmacol; 2022 Nov; 88(11):4663-4675. PubMed ID: 35853612 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases. Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119 [TBL] [Abstract][Full Text] [Related]
6. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis. Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512 [TBL] [Abstract][Full Text] [Related]
7. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Larsen TB; Gorst-Rasmussen A; Rasmussen LH; Skjøth F; Rosenzweig M; Lip GY Am J Med; 2014 Jul; 127(7):650-656.e5. PubMed ID: 24530792 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Sharma M; Cornelius VR; Patel JP; Davies JG; Molokhia M Circulation; 2015 Jul; 132(3):194-204. PubMed ID: 25995317 [TBL] [Abstract][Full Text] [Related]
9. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Carmo J; Moscoso Costa F; Ferreira J; Mendes M Thromb Haemost; 2016 Sep; 116(4):754-63. PubMed ID: 27465747 [TBL] [Abstract][Full Text] [Related]
10. Direct oral anticoagulation in atrial fibrillation and heart valve surgery-a meta-analysis and systematic review. Gerfer S; Djordjevic I; Eghbalzadeh K; Mader N; Wahlers T; Kuhn E Ther Adv Cardiovasc Dis; 2022; 16():17539447221093963. PubMed ID: 35481366 [TBL] [Abstract][Full Text] [Related]
11. Major Hemorrhage Risk Associated with Direct Oral Anticoagulants in Non-Valvular Atrial Fibrillation: A Systematic Review and Meta-Analysis. Archontakis-Barakakis P; Kokkinidis DG; Nagraj S; Gidwani V; Mavridis T; Ntaios G Rev Cardiovasc Med; 2022 Oct; 23(10):334. PubMed ID: 39077138 [TBL] [Abstract][Full Text] [Related]
12. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?]. Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L Semergen; 2018; 44(5):297-303. PubMed ID: 28867369 [TBL] [Abstract][Full Text] [Related]
13. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Staerk L; Fosbøl EL; Lip GYH; Lamberts M; Bonde AN; Torp-Pedersen C; Ozenne B; Gerds TA; Gislason GH; Olesen JB Eur Heart J; 2017 Mar; 38(12):907-915. PubMed ID: 27742807 [TBL] [Abstract][Full Text] [Related]
14. An Evidence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Meta-Analysis. Suppah M; Kamal A; Saadoun R; Baradeiya AMA; Abraham B; Alsidawi S; Sorajja D; Fortuin FD; Arsanjani R Am J Cardiol; 2023 Nov; 206():132-150. PubMed ID: 37703679 [TBL] [Abstract][Full Text] [Related]
15. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials. Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4-5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study. Lin Y; Chao TF; Tsai ML; Tseng CJ; Wang TH; Chang CH; Lin YS; Yang NI; Chu PH; Hung MJ; Wu VC; Chen TH J Thromb Thrombolysis; 2024 Jan; 57(1):89-100. PubMed ID: 37605063 [TBL] [Abstract][Full Text] [Related]
17. Oral anticoagulant switching in patients with atrial fibrillation: a scoping review. Adelakun AR; Turgeon RD; De Vera MA; McGrail K; Loewen PS BMJ Open; 2023 Apr; 13(4):e071907. PubMed ID: 37185198 [TBL] [Abstract][Full Text] [Related]
18. Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation. Hellfritzsch M; Wang SV; Grove EL; Gagne JJ; Hallas J; Pottegård A Am J Epidemiol; 2020 Dec; 189(12):1467-1477. PubMed ID: 32639512 [TBL] [Abstract][Full Text] [Related]
19. Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. Souverein PC; van den Ham HA; Huerta C; Merino EM; Montero D; León-Muñoz LM; Schmiedl S; Heeke A; Rottenkolber M; Andersen M; Aakjaer M; De Bruin ML; Klungel OH; Gardarsdottir H Br J Clin Pharmacol; 2021 Mar; 87(3):988-1000. PubMed ID: 32627222 [TBL] [Abstract][Full Text] [Related]
20. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: A meta-analysis. Yokoyama Y; Briasoulis A; Ueyama H; Mori M; Iwagami M; Misumida N; Takagi H; Kuno T J Thorac Cardiovasc Surg; 2023 Jun; 165(6):2052-2059.e4. PubMed ID: 34417050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]